

**FORM 13-502F1**  
**CLASS 1 AND CLASS 3B REPORTING ISSUERS - PARTICIPATION FEE**

**MANAGEMENT CERTIFICATION**

I, Photios Michalargias, an officer of the reporting issuer noted below have examined this Form 13-502F1 (the **Form**) being submitted hereunder to the Ontario Securities Commission and certify that to my knowledge, having exercised reasonable diligence, the information provided in the Form is complete and accurate.

(s) "Photios Michalargias"

Name: Photios Michalargias

Title: Chief Financial Officer

December 9, 2021

Date:

**Reporting Issuer Name:** Helix BioPharma Corp.

**End date of previous financial year:** July 31, 2021

**Type of Reporting Issuer:**  **Class 1 reporting issuer**  **Class 3B reporting issuer**

**Highest Trading Marketplace:** Toronto Stock Exchange

(refer to the definition of "highest trading marketplace" under OSC Rule 13-502 Fees)

**Market value of listed or quoted equity securities:**

(in Canadian Dollars - refer to section 7.1 of OSC Rule 13-502 Fees)

**Equity Symbol** HBP

**1<sup>st</sup> Specified Trading Period** (dd/mm/yy)

(refer to the definition of "specified trading period" under OSC Rule 13-502 Fees)

01/08/2020 to 31/10/2020

Closing price of the security in the class or series on the last trading day of the specified trading period in which such security was listed or quoted on the highest trading marketplace

\$ 0.850 (i)

Number of securities in the class or series of such security outstanding at the end of the last trading day of the specified trading period

132,933,017 (ii)

Market value of class or series

(i) x (ii) \$ 112,933,064.45 (A)

**2<sup>nd</sup> Specified Trading Period (dd/mm/yy)**

(refer to the definition of “specified trading period” under OSC Rule 13-502 Fees)

01/11/2020 to 31/01/2021

Closing price of the security in the class or series on the last trading day of the specified trading period in which such security was listed or quoted on the highest trading marketplace

\$ 0.820 (iii)

Number of securities in the class or series of such security outstanding at the end of the last trading day of the specified trading period

141,133,017 (iv)

Market value of class or series

(iii) x (iv) \$ 115,729,073.94 (B)

**3<sup>rd</sup> Specified Trading Period (dd/mm/yy)**

(refer to the definition of “specified trading period” under OSC Rule 13-502 Fees)

01/02/2021 to 30/04/2021

Closing price of the security in the class or series on the last trading day of the specified trading period in which such security was listed or quoted on the highest trading marketplace

\$ 0.570 (v)

Number of securities in the class or series of such security outstanding at the end of the last trading day of the specified trading period

141,133,017 (vi)

Market value of class or series

(v) x (vi) \$ 80,445,819.69 (C)

**4<sup>th</sup> Specified Trading Period (dd/mm/yy)**

(refer to the definition of “specified trading period” under OSC Rule 13-502 Fees)

01/05/2021 to 31/07/2021

Closing price of the security in the class or series on the last trading day of the specified trading period in which such security was listed or quoted on the highest trading marketplace

\$ 0.540 (vii)

Number of securities in the class or series of such security outstanding at the end of the last trading day of the specified trading period

141,133,017 (viii)

Market value of class or series

(vii) x (viii) \$ 76,211,829.18 (D)

**5<sup>th</sup> Specified Trading Period (dd/mm/yy)**

(refer to the definition of “specified trading period” under OSC Rule 13-502 Fees)

N/A to N/A

Closing price of the security in the class or series on the last trading day of the specified trading period in which such security was listed or quoted on the highest trading marketplace \$           N/A           (ix)

Number of securities in the class or series of such security outstanding at the end of the last trading day of the specified trading period           N/A           (x)

Market value of class or series (ix) x (x) \$           N/A           (E)

**Average Market Value of Class or Series**

(Calculate the simple average of the market value of the class or series of security for each applicable specified trading period (i.e. A through E above))

\$   96,332,446.64   (1)

(Repeat the above calculation for each other class or series of equity securities of the reporting issuer (and a subsidiary pursuant to paragraph 2.8(1)(c) of OSC Rule 13-502 *Fees*, if applicable) that was listed or quoted on a marketplace at the end of the previous financial year)

**Fair value of outstanding debt securities:**

(See paragraph 2.8(1)(b), and if applicable, paragraph 2.8(1)(c) of OSC Rule 13-502 *Fees*)

\$           N/A           (2)

(Provide details of how value was determined)

(represents the aggregate principal amount of convertible debenture debt outstanding)

**Capitalization for the previous financial year** (1) + (2) \$   96,332,446.64  

**Participation Fee**

(For Class 1 reporting issuers, from Appendix A of OSC Rule 13-502 *Fees*, select the participation fee)

\$   6,390.00  

(For Class 3B reporting issuers, from Appendix A.1 of OSC Rule 13-502 *Fees*, select the participation fee)

**Late Fee, if applicable**

(As determined under section 2.7 of OSC Rule 13-502 *Fees*)

\$   2,900.00  

**Total Fee Payable**

(Participation Fee plus Late Fee)

\$   9,290.00